ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0605

Determining the ECG Cut-off Point in Systemic Lupus Erythematosus Patients Undergoing Hydroxychloroquine Therapy

Carmen Lasa1, Alba Herrero-Morant2, Jon Zubiaur3, Adrián Margarida4, Raquel Pérez3 and Ricardo Blanco5, 1Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, 2Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 3Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla., Santander, Spain, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Meeting: ACR Convergence 2023

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0582–0608) SLE – Treatment Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Hydroxychloroquine (HCQ) is a widely used drug in Systemic Lupus Erythematosus (SLE) that can cause cardiac alterations such as arrhythmic events in the short-term and dose-dependent cardiomyopathy in the medium to long-term. The cardiological implications of HCQ accumulation in these patients in the medium to long-term is unknown.

Methods: Single university hospital observational study of all consecutive SLE patients who had an electrocardiogram (ECG) at baseline and at least one ECG at follow-up. New conduction disturbances were assessed by ECG, defined as atrioventricular block, bundle branch block or QT interval prolongation. ECGs were extracted from the medical record and interpreted at baseline and for 15.2 years (95%CI 13.24-17.16) of follow-up. We defined cumulative HCQ (cHCQ) as the total grams of HCQ that had been administered. A ROC curve analysis was performed to determine the optimal cut-off point for sensitivity and specificity.

Results: We studied 105 (93 female/12 male) SLE patients with a mean (±SD) age of 61.8±14.9 years. The mean daily dose of HCQ in our sample was 256 mg per day (Table). The ROC curve showed a moderate diagnostic ability for new conduction disturbances with an area under the curve of 0.69 (95% CI 0.59 – 0.77) (Figure). The highest efficacy cut-off point was cHCQ: 4097g (Sensitivity 15%; Specificity 100%) and the optimal cut-off point was cHCQ: 901g (Sensitivity 85%; Specificity 52.9%). This cut-off point was reached with a mean HCQ treatment in our sample of 9.7 years. High grade atrio-ventricular block was found in 5 patients. In all of them the cHCQ dose was over 901g.

Conclusion: According to our study, 901g of cumulative HCQ dose is a good cut-off point for performing a protocolized ECG to rule out cardiac conduction disturbances in patients with SLE and chronic HCQ treatment. This is equivalent to 9.7 years of treatment with the mean HCQ dose use in our sample.

Supporting image 1

Supporting image 2


Disclosures: C. Lasa: None; A. Herrero-Morant: None; J. Zubiaur: None; A. Margarida: None; R. Pérez: None; R. Blanco: AbbVie, 5, 6, Amgen, 6, AstraZeneca, 2, BMS, 6, Eli Lilly, 6, Galapagos, 2, 6, Janssen, 2, 6, MSD, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 5, 6, Sanofi, 6.

To cite this abstract in AMA style:

Lasa C, Herrero-Morant A, Zubiaur J, Margarida A, Pérez R, Blanco R. Determining the ECG Cut-off Point in Systemic Lupus Erythematosus Patients Undergoing Hydroxychloroquine Therapy [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/determining-the-ecg-cut-off-point-in-systemic-lupus-erythematosus-patients-undergoing-hydroxychloroquine-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/determining-the-ecg-cut-off-point-in-systemic-lupus-erythematosus-patients-undergoing-hydroxychloroquine-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology